Spots Global Cancer Trial Database for Cemiplimab/Peg-Interferon-α in Advanced CSCC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Cemiplimab/Peg-Interferon-α in Advanced CSCC
Official Title: Cemiplimab/PEG-Interferon-α Combination for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)
Study ID: NCT05729139
Study Description
Brief Summary: The primary purpose of this research study is to test the safety and possible harms of cemiplimab/peg-interferon-alpha, when it is given to participants at different dose levels. The researchers want to find out what effects (good and bad) cemiplimab/Peg-Interferon has on participants with advanced cutaneous squamous cell carcinoma (aCSCC) so that they can find the best dose to treat aCSCC and reduce side effects as much as possible.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States
Contact Details
Name: Guilherme Rabinowits, M.D.
Affiliation: Miami Cancer Institute at Baptist Health, Inc.
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
